Qin Sina, Chen Meng-Hua, Fang Wei, Tan Xiao-Feng, Xie Lu, Yang Ye-Gui, Qin Tao, Li Nuo
Intensive Care Unit, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Drug Des Devel Ther. 2019 Aug 7;13:2759-2768. doi: 10.2147/DDDT.S215358. eCollection 2019.
Various and opposite roles of epigallocatechin gallate (EGCG) have been reported in different studies. We aimed to investigate how EGCG affects the cerebral injury in a cardiac arrest/cardiopulmonary resuscitation (CA/CPR) model of rat.
The rats which were subjected to CA/CPR randomly received low dose of EGCG (3 mg/kg, Low-EGCG group, n=16), high dose of EGCG (9 mg/kg, High-EGCG group, n=16) and equal volume of 0.9% saline solution (NS group, n=16) at the first minute after return of spontaneous circulation (ROSC). The rats underwent anesthesia and intubation were defined as Sham group (n=16). Twenty-four hours after ROSC, neural defect score (NDS), ROS fluorescence intensity, degree of mitochondrial permeability transition pore (mPTP) opening, ATP contents and mitochondrial ATP synthase expression were evaluated in the four groups. The expression of extracellular signal-regulated kinase (ERK) activity and cleaved-caspase 3 were also detected by Western blot.
CA/CPR induced severe ischemia-reperfusion injury (IRI), resulted in mitochondrial dysfunction and upregulated phosphorylation of ERK. EGCG dose-dependently alleviated the IRI after CA/CPR, inhibited ERK activity and restored mitochondrial function and, as indicated by improved NDS, reduced ROS level, decreased mPTP opening, elevated ATP content, increased ATPase expression and downregulated cleaved-caspase 3 level.
EGCG alleviated global cerebral IRI by restoring mitochondrial dysfunction and ERK modulation in a rat CA/CPR model, which might make it a potential candidate agent against IRI after CA/CPR in the future. Further study is needed to determine whether higher dosage of EGCG might aggravate cerebral IRI post-CA/CPR.
在不同研究中已报道表没食子儿茶素没食子酸酯(EGCG)具有多种相反的作用。我们旨在研究EGCG如何影响大鼠心脏骤停/心肺复苏(CA/CPR)模型中的脑损伤。
经历CA/CPR的大鼠在自主循环恢复(ROSC)后的第一分钟随机接受低剂量EGCG(3mg/kg,低剂量EGCG组,n = 16)、高剂量EGCG(9mg/kg,高剂量EGCG组,n = 16)和等体积的0.9%盐溶液(生理盐水组,n = 16)。接受麻醉和插管的大鼠定义为假手术组(n = 16)。ROSC后24小时,评估四组的神经缺陷评分(NDS)、活性氧(ROS)荧光强度、线粒体通透性转换孔(mPTP)开放程度、ATP含量和线粒体ATP合酶表达。还通过蛋白质免疫印迹法检测细胞外信号调节激酶(ERK)活性和裂解的半胱天冬酶-3的表达。
CA/CPR诱导严重的缺血再灌注损伤(IRI),导致线粒体功能障碍并上调ERK磷酸化。EGCG剂量依赖性地减轻CA/CPR后的IRI,抑制ERK活性并恢复线粒体功能,表现为NDS改善、ROS水平降低、mPTP开放减少、ATP含量升高、ATP酶表达增加以及裂解的半胱天冬酶-3水平下调。
在大鼠CA/CPR模型中,EGCG通过恢复线粒体功能障碍和ERK调节减轻全脑IRI,这可能使其成为未来对抗CA/CPR后IRI的潜在候选药物。需要进一步研究以确定更高剂量的EGCG是否会加重CA/CPR后脑IRI。